How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort

Christina Fotopoulou

doi:10.3802/jgo.2020.31.e26

Journal List > J Gynecol Oncol > v.31(1) > 1148329

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Fotopoulou: How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort

Editorial

J Gynecol Oncol 2020;31(1):e26.

Published online: 4 January 2020

DOI: https://doi.org/10.3802/jgo.2020.31.e26

How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort

Christina Fotopoulou

Department of Surgery and Cancer, Imperial College London, West London Gynecological Cancer Center, Imperial College Healthcare NHS Trust, London, UK

Correspondence to Christina Fotopoulou Department of Surgery and Cancer, Imperial College London, West London Gynecological Cancer Center, Imperial College Healthcare NHS Trust, S Wharf Rd, Paddington, London W2 1NY, UK. E-mail: chfotopoulou@gmail.com

Received 12 October 2019 Revised 14 October 2019 Accepted 14 October 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20:1248–59.

2. Hall M, Savvatis K, Nixon K, Kyrgiou M, Hariharan K, Padwick M, et al. Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome. Ann Surg Oncol. 2019; 26:2943–51.

3. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15:668–79.

4. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363:943–53.

5. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386:249–57.

6. Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D, et al. Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol. 2017; 35:587–90.

7. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016; 34:3854–63.

8. Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, et al. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. J Gynecol Oncol. 2020; 31:e17.

9. Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019; 29:1327–31.

10. Clamp AR, McNeish IA, Dean A, Gallardo-Rincon D, Kim J-W, O'Donnell DM, et al. Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment. Ann Oncol. 2018; 29:viii336.

TOOLS

Similar articles